Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

• Status: Terminated
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the study is to evaluate the effect, safety and tolerability of CDP323 in patients with relapsing forms of multiple sclerosis

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UCB Pharma
• Collaborator: Biogen

Criteria

Inclusion Criteria:

• relapsing form of MS

• screening EDSS score 0 - 5.5, inclusive

• at least one clinical relapse in the 12 months before screening

• active disease, defined by set of MRI activity criteria

• failed prior treatment with beta-interferons or glatiramer acetate

Exclusion Criteria:

• signs of silent infections, including positive tests for HIV1, HIV2 or Hepatitis B or Hepatitis C or tuberculosis

• known allergy to gadolinium-DTPA, and/or ingredients of the study drug formulation

• pre-treatment with immunosuppressive or immunomodulatory drugs prior to screening within certain time frames